- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06674863
Plan de atención de supervivencia personalizado para mejorar la comprensión y el acceso a la atención de supervivencia en pacientes negros o afroamericanos con cáncer de próstata localizado u oligometastásico
Abordar la alfabetización sanitaria con un plan de atención de supervivencia personalizado para mejorar el acceso en pacientes afroamericanos con cáncer de próstata desatendidos
This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVES:
I. Compare outcomes after patients receive usual care from their providers with a standard SCP and after patients receive tailoring of the SCP with the low literacy educational supplement.
II. To quantify the potential benefit of tailoring the care plan and the educational supplement.
III. Compare providers' assessment of patients':
IIIa. Health literacy; IIIb. Comprehension of survivorship care recommendations; IIIc. Understanding of long term and late effects from treatment; IIId. To measures obtained from patients.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (INTERVENTION): Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes.
GROUP II (CONTROL): Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Kerry L. Kilbridge, MD, MSc
- Número de teléfono: 617-632-2429
- Correo electrónico: Kerry_Kilbridge@DFCI.HARVARD.EDU
Ubicaciones de estudio
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University Hospital/Winship Cancer Institute
-
Contacto:
- Sierra Williams
- Número de teléfono: 404-778-4898
- Correo electrónico: sierra.williams@emory.edu
-
Investigador principal:
- Viraj Master, MD, PhD, FACS
-
Atlanta, Georgia, Estados Unidos, 30303
- Reclutamiento
- Grady Memorial Hospital
-
Contacto:
- Sierra Williams
- Número de teléfono: 404-778-4729
- Correo electrónico: sierra.williams@emory.edu
-
Investigador principal:
- Viraj Master, MD, PhD, FACS
-
Atlanta, Georgia, Estados Unidos, 30329
- Reclutamiento
- Atlanta VA Medical Center
-
Contacto:
- Sierra Williams
- Número de teléfono: 404-778-4729
- Correo electrónico: sierra.williams@emory.edu
-
Investigador principal:
- Mohammad Hajiha, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Black and African American men who are disease-free after completing primary surgery and/or radiation treatment for localized or oligometastatic prostate cancer between 1 to 4 years prior to enrollment. (Race/ethnicity per medical records and self report)
- Patients who are still receiving adjuvant androgen deprivation therapy following primary radiation with non-palliative intent may be included
Exclusion Criteria:
- Dementia or cognitive impairment per provider clinical assessment
- Unable to give informed consent in the judgement of the patient's oncology provider
- Recurrent prostate cancer after primary treatment
- Less than 18 years of age at the time of informed consent
- Diagnosis of active second malignancy requiring treatment
- Individuals who are not able to clearly understand English since the outcome measures require understanding of English
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Group I (standard SCP, tailored SCP)
Patients receive standard SCP during a provider visit and a tailored SCP with a low literacy educational supplement during a structured interview over 30-60 minutes. |
Ancillary studies Receive a low literacy educational supplement
Otros nombres:
Undergo a structured interview Receive standard SCP
Otros nombres:
Receive a tailored SCP
Otros nombres:
|
|
Comparador activo: Group II (standard SCP)
Patients receive standard SCP using the prostate cancer ASCO template during a provider visit and undergo a structured interview over 30-60 minutes. |
Ancillary studies Undergo a structured interview Receive standard SCP
Otros nombres:
Receive a tailored SCP
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Comprehension of survivorship care recommendations and prostate specific antigen surveillance
Periodo de tiempo: At baseline and up to 3 month phone call
|
Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard survivorship care plan (SCP) compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05. |
At baseline and up to 3 month phone call
|
|
Comprehension of treatment side effects and late effects
Periodo de tiempo: At baseline and up to 3 month phone call
|
Comprehension will be scored as dichotomous variables, correct or incorrect. The proportion of patients who correctly understand after the standard SCP compared to the proportion who correctly understand after the standard SCP + tailoring + educational support will be analyzed using a two-tailed Z-score test for equality of two proportions at a significance level of P < 0.05. |
At baseline and up to 3 month phone call
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Access to survivorship care for late and long-term side effects
Periodo de tiempo: At baseline and up to 3 month phone call
|
Will be assessed using the Patients Access Score (PAS). Descriptive statistics will be used to characterize patient access to survivorship care. The difference in mean PAS will be compared between the two arms using a 2 sample t-test. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Linear regression models will be used to identify predictors of access to survivorship care. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Decision regret
Periodo de tiempo: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize decision regret. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Change in decisional conflict
Periodo de tiempo: At baseline and up to 3 month phone call
|
The two-sample t-test will be used to evaluate the change in the average decisional conflict score between patients in the control arm (standard SCP) and patients in the intervention arm (standard SCP + tailoring + educational supplement). |
At baseline and up to 3 month phone call
|
|
Preparedness for survivorship
Periodo de tiempo: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize preparedness for survivorship. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
|
Patient self-efficacy
Periodo de tiempo: At baseline and up to 3 month phone call
|
Descriptive statistics will be used to characterize patient self-efficacy. Results will be compared to previous studies, published work, and other historical cohorts. The concordance of urologists' assessment of patients' outcomes with outcomes obtained from patients will be analyzed as the percent of concordant responses, and with unweighted and weighted kappa coefficients. Parsimonious models will be favored due to the relatively small sample size. |
At baseline and up to 3 month phone call
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Viraj Master, MD, PhD, FACS, Emory University Hospital/Winship Cancer Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Neoplasias prostáticas
- Calidad, acceso y evaluación de la atención médica
- Técnicas de investigación
- Métodos epidemiológicos
- Terapéutica
- Recopilación de datos
- Mecanismos de evaluación de atención médica
- Calidad de la atención médica
- Salud pública
- Medio ambiente y salud pública
- Atención al paciente
- Servicios de salud
- Instalaciones de atención médica Fuerza laboral y servicios
- Servicios de salud infantil
- Servicios de salud comunitarios
- Servicios de salud preventivos
- Factores socioeconómicos
- Características de la población
- Métodos
- Entrevistas como tema
- Cuidados paliativos
- Intervención temprana, educativa
- Estado educativo
Otros números de identificación del estudio
- STUDY00008365
- P30CA138292 (Subvención/contrato del NIH de EE. UU.)
- STUDY00008365 (Otro identificador: Emory University Hospital/Winship Cancer Institute)
- NCI-2024-08650 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- WINSHIP6368-24 (Otro identificador: Emory University Hospital/Winship Cancer Institute)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .